Pharmacokinetic drug interactions between drugs of abuse and antiretroviral medications: Implications and management for clinical practice

Expert Review of Clinical Pharmacology

Volumn 1, Issue 1, 2008, Pages 115-127

  Bruce, R Douglas ^a   Altice, Frederick L ^a   Friedland, Gerald H ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXYBUTYRIC ACID; ABACAVIR; ALCOHOL; AMYL NITRITE; BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; BUTYL NITRITE; COCAINE; DIDANOSINE; EFAVIRENZ; ISOBUTYL NITRITE; KETAMINE; LAMIVUDINE; METHADONE; METHAMPHETAMINE; MIDAZOLAM; NEVIRAPINE; OPIATE DERIVATIVE; PHENCYCLIDINE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TETRAHYDROCANNABINOL DERIVATIVE; UNINDEXED DRUG; ZIDOVUDINE;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMNESIA; ANEMIA; AREA UNDER THE CURVE; CARDIOTOXICITY; CASE STUDY; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DEPENDENCE; DRUG DISPOSITION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; DRUG POTENTIATION; DRUG TISSUE LEVEL; DRUG USE; ENTERIC COATED TABLET; ENZYME INHIBITION; FATIGUE; HEALTH CARE ACCESS; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRRITABILITY; LIVER METABOLISM; MEDLINE; MYALGIA; NONHUMAN; PAIN; PATIENT CARE; PATIENT COMPLIANCE; PROCESS OPTIMIZATION; REVIEW; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; SUBSTANCE ABUSE; TABLET FORMULATION; URINARY EXCRETION; WITHDRAWAL SYNDROME;

EID: 38349002778     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/17512433.1.1.115     Document Type: Review

References (170)

1. Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. Clin. Infect. Dis. 45, 770-778 (2007).
2. Macalino GE, Hogan JW, Mitty JA et al. A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users. AIDS 21, 1473-1477 (2007).
3. Fromm MF. Importance of P-glycoprotein for drug disposition in humans. Eur. J. Clin. Invest. 33 (Suppl. 2), 6-9 (2003).
4. Watkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv. Drug Deliv. Rev. 27, 161-170 (1997).
5. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl Acad. Sci. USA 84, 7735-7738 (1987).
6. Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem. Pharmacol. 73, 1573-1581 (2007).
7. Tong L, Phan TK, Robinson KL et al. Effects of HIV protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob. Agents Chemother. 51(10), 3498-3504 (2007).
8. Ding R, Tayrouz Y, Riedel KD et al. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin. Pharmacol. Ther. 76, 73-84 (2004).
9. Rios GR, Tephly TR. Inhibition and active sites of UDP-glucuronosyltransferases 2B7 and 1A1. Drug Metab. Dispos. 30, 1364-1367 (2002).
10. Markowitz M, Morales-Ramirez JO, Nguyen BY et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr. 43, 509-515 (2006).
11. Kassahun K, McIntosh IS, Hreniuk D et al. Absorption, metabolism and excretion of MK-0518, a potent HIV-1 integrase inhibitor, in healthy male volunteers. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy 46th Annual Meeting. San Francisco, CA, USA, 27-30 September, 2006.
12. Ventura J, Wenning LA, Troyer, MD et al. Lack of a pharmacokinetic interaction of MK-0518 on midazolam (MDZ). Presented at: Eighth International Congress on Drug Therapy in HIV Infection. Glasgow, UK, 12-16 November 2006.
13. Grinsztejn B, Nguyen BY, Katlama C et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a Phase II randomised controlled trial. Lancet 369, 1261-1269 (2007).
14. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 356, 1667-1671 (2000).
15. Sommadossi JP. Cellular nucleoside pharmacokinetics and pharmacology: a potentially important determinant of antiretroviral efficacy. AIDS 12(Suppl. 3), S1-S8 (1998).
16. Beach JW. Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions. Clin. Ther. 20, 2-25 (1998).
17. Sankatsing SU, Beijnen JH, Schinkel AH, Lange JM, Prins JM. P glycoprotein in human immunodeficiency virus type 1 infection and therapy. Antimicrob. Agents Chemother. 48, 1073-1081 (2004).
18. Veal GJ, Back DJ. Metabolism of zidovudine. Gen. Pharmacol. 26, 1469-1475 (1995).
19. Decks SG, Barditch-Crovo P, Lietman PS et al. Safety; pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl] adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob. Agents Chemother. 42, 2380-2384 (1998).
20. Safrin S. Antiviral agents. In: Basic & Clinical Pharmacology (9th Edition). Katzung BG (Ed.). The McGraw-Hill Companies, Inc., Columbus, OH, USA (2004).
21. Heald AE, Hsyu PH, Yuen GJ, Robinson P, Mydlow P, Bartlett JA. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob. Agents Chemother. 40, 1514-1519 (1996).
22. Emtriva™. Product information. Emtricitabine. Bristol-Myers Squibb, Wallingford, CT, USA (2003).
23. Csajka C, Marzolini C, Fattinger K et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin. Pharmacol. Ther. 73, 20-30 (2003).
24. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15, 71-75 (2001).
25. Riska P, Erickson D, Joseph D et al. Nevirapine, a nonnucleoside reverse transcriptase inhibitor: metabolism in man, mouse, rat, dog, cynomolgus monkey and chimpanzee. Presented at: XI International Conference on AIDS. Vancouver, BC, Canada, 7-12 July 1996.
26. Sustiva. Product information. DuPont Pharmaceuticals, Wilmington, DE, USA (1998).
27. Gerber JG, Rosenkranz SL, Fichtenbaum CJ et al. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J. Acquir. Immune Defic. Syndr. 39(3), 307-312 (2005).
28. Tran JQ, Gerber JG, Kerr BM. Delavirdine: clinical pharmacokinetics and drug interactions. Clin. Pharmacokinet. 40, 207-226 (2001).
29. Kappelhoff BS, Crommentuyn KM, de Mast MM, Mulder JW, Huitema AD, Beijnen JH. Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin. Pharmacokinet. 43, 845-853 (2004).
30. Flexner C. HIV-protease inhibitors. N. Engl. J. Med. 338, 1281-1292 (1998).
31. Decker CJ, Laitinen LM, Bridson GW, Raybuck SA, Tung RD. Chaturvedi PR. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J. Pharm. Sci. 87, 803-807 (1998).
32. Prezista™, product information, darunavir. Tibotec Therapeutics, Raritan, NJ, USA (2006).
33. Yeni P. Tipranavir: a protease inhibitor from a new class with distinct antiviral activity J. Acquir. Immune Defic. Syndr. 34(Suppl. 1), S91-S94 (2003).
34. Hansten PD. Drug Interactions. Vancouver: Applied Therapeutics, Inc.; (1995).
35. Faragon JJ, Piliero PJ. Drug interactions associated with HAART: focus on treatments for addiction and recreational drugs. AIDS Read. 13, 433-434 (2003).
36. Vourvahis M, Kashuba AD. Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir. Pharmacotherapy 27, 888-909 (2007).
37. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab. Dispos. 33, 1729-1739 (2005).
38. Lankisch TO, Moebius U, Wehmeier M et al. Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype. Hepatology 44, 1324-1332 (2006).
39. Dorr P, Westby M, Dobbs S et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49, 4721-4732 (2005).
40. Wood A, Armour D. The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS. Prog. Med. Chem. 43, 239-271 (2005).
41. Abel S et al. The effect of CYP3A4 inhibitors on the pharmacokinetics of CCR5 antagonist UK-427,857 in healthy volunteers. Presented at: 5th International Workshop on Clinical Pharmacology of HIV Therapy. Rome, Italy, 1-3 April 2004.
42. Jenkins T, Abel S, Russell D et al. The effect of P450 inducers on the pharmacokinetics of CCR5 antagonist UK-427,857 in healthy volunteers. Presented at: 5th International Workshop on Clinical Pharmacology in HIV Therapy. Rome, Italy, 1-3 April 2004.
43. Mistry G, Wenning LA, Merchman et al. Atazanavir and ritonavir increase plasma levels of MK-0518. Presented at: Eighth International Congress on Drug Therapy in HIV Infection. Glasgow, UK 12-16 November 2006.
44. Patel IH, Zhang X, Nieforth K, Salgo M, Buss N. Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Clin. Pharmacokinet. 44, 175-186 (2005).
45. Woodward JJ. The pharmacology of alcohol. In: Principles of Addiction Medicine (3rd Edition). Graham AW, Schultz TK, Mayo-Smith MF, Ries R Wilford BB (Eds). American Society of Addiction Medicine, MD, USA 101-118 (2003).
46. Niemela O, Parkkila S, Juvonen RO, Viitala K, Gelboin HV, Pasanen M. Cytochromes P450 2A6, 2E1, and 3A and production of protein-aldehyde adducts in the liver of patients with alcoholic and non-alcoholic liver diseases. J. Hepatol. 33, 893-901 (2000).
47. Novak RF, Woodcroft KJ. The alcohol-inducible form of cytochrome P450 (CYP2E1): role in toxicology and regulation of expression. Arch. Pharm. Res. 23, 267-282 (2000).
48. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 27, 128-133 (1998).
49. Hu Y, Ingelman-Sundberg M, Lindros KO. Induction mechanisms of cytochrome P450 2E1 in liver: interplay between ethanol treatment and starvation. Biochem. Pharmacol. 50, 155-161 (1995).
50. Badger TM, Huang J, Ronis M, Lumpkin CK. Induction of cytochrome P450 2E1 during chronic ethanol exposure occurs via transcription of the CYP 2E1 gene when blood alcohol concentrations are high. Biochem. Biophys. Res. Commun. 190, 780-785 (1993).
51. Ronis MJ, Huang J, Crouch J et al. Cytochrome P450 CYP 2E1 induction during chronic alcohol exposure occurs by a two-step mechanism associated with blood alcohol concentrations in rats. J. Pharmacol. Exp. Ther. 264, 944-950 (1993).
52. Salmela KS, Kessova IG, Tsyrlov IB, Lieber CS. Respective roles of human cytochrome P-4502E1, 1A2, and 3A4 in the hepatic microsomal ethanol oxidizing system. Alcohol. Clin. Exp. Res. 22, 2125-2132 (1998).
53. Kresina TF, Flexner CW, Sinclair J et al. Alcohol use and HIV pharmacotherapy. AIDS Res. Hum. Retroviruses 18, 757-770 (2002).
54. Raucy JL, Schultz ED, Kearins MC et al. CYP2E1 expression in human lymphocytes from various ethnic populations. Alcohol Clin. Exp. Res. 23, 1868-1874 (1999).
55. McDowell JA, Chittick GE, Stevens CP, Edwards KD, Stein DS. Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. 44, 1686-1690 (2000).
56. Flexner CW, Cargill VA, Sinclair J, Kresina TF, Cheever L. Alcohol use can result in enhanced drug metabolism in HIV pharmacotherapy. AIDS Patient Care STDS 15, 57-58 (2001).
57. Barber TJ, Marett B, Waldron S et al. Are disulfiram-like reactions associated with abacavir-containing antiretroviral regimens in clinical practice? AIDS 21, 1823-1824 (2007).
58. Pence BW, Miller WC, Gaynes BN, Eron JJ Jr. Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy. J. Acquit. Immune Defic. Syndr. 44, 159-166 (2007).
59. Peretti-Watel P, Spire B, Lert F, Obadia Y. Drug use patterns and adherence to treatment among HIV-positive patients: evidence from a large sampie of French outpatients (ANRS-EN12-VESPA 2003). Drug Alcohol Depend. 82(Suppl. 1), S71-S79 (2006).
60. Cohen S. The volatile nitrites. JAMA 241, 2077-2078 (1979).
61. Haverkos HW, Dougherty J. Health hazards of nitrite inhalants. Am. J. Med. 84, 479-482 (1988).
62. Waldo CR, McFarland W, Katz MH, MacKellar D, Valleroy LA. Very young gay and bisexual men are at risk for HIV infection: the San Francisco Bay Area Young Men's Survey II. J. Acquir. Immune Defic. Syndr. 24, 168-174 (2000).
63. Hidaka Y, Ichikawa S, Koyano J et al. Substance use and sexual behaviours of Japanese men who have sex with men: a nationwide internet survey conducted in Japan. BMC Public Health 6, 239 (2006).
64. Brewer DD, Golden MR, Handsfield HH. Unsafe sexual behavior and correlates of risk in a probability sample of men who have sex with men in the era of highly active antiretroviral therapy. Sex. Transm. Dis. 33, 250-255 (2006).
65. Smith KM, Romanelli F. Recreational use and misuse of phosphodiesterase 5 inhibitors. J. Am. Pharm. Acsoc. 45, 63-72 (2005).
66. Wynn GH, Cozza KL, Zapor MJ, Wortmann GW, Armstrong SC. Med-psych drug-drug interactions update. Antiretrovirals, part III: antiretrovirals and drugs of abuse. Psychosomatics 46, 79-87 (2005).
67. Denis C, Fatseas M, Lavie E, Auriacombe M. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. Cochrane Database Syst. Rev. 3, CD005194 (2006).
68. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet. 38, 41-57 (2000).
69. Yuan R, Flockhart DA, Balian JD. Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triszolam. J. Clin. Pharmacol. 39, 1109-1125 (1999).
70. Allqvist A, Miura J, Bertilsson L, Mirghani RA. Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers. Eur. J. Clin. Pharmacol. 63, 173-179 (2007).
71. Greenblatt DJ, von Moltke LL, Daily JP, Harmatz JS, Shader RI. Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction. J. Clin. Psychopharmacol. 19, 293-296 (1999).
72. Greenblatt DJ, von Moltke LL, Harmatz JS et al. Alprazolam-ritonavir interaction: implications for product labeling. Clin. Pharmacol. Ther. 67, 335-341 (2000).
73. Frye R, Bertz R, Granneman GR et al. Effect of ritonavir on the pharmacokinetics and pharmacodynamics of alprazolam. Presented at: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, ON, Canada, 28 September-1 October 1997.
74. Merry C, Mulcahy F, Barry M, Gibbons S, Back D. Saquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV disease. AIDS 11, 268-269 (1997).
75. Palkama VJ, Ahonen J, Neuvonen PJ, Olkkola KT. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. Clin. Pharmacol. Ther. 66, 33-39 (1999).
76. Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. [Erratum appears in Clin. Pharmacokinet. 35(6), 473 (1998)]. Clin. Pharmacokinet. 35, 275-291 (1998).
77. Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf. 18, 83-97 (1998).
78. Le Tiec C, Barrail A, Goujard C, Taburet AM. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin. Pharmacokinet. 44, 1035-1050 (2005).
79. Chung JY, Cho JY, Yu KS et al. Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. Clin. Pharmacol. Ther. 77, 486-494 (2005).
80. Inomata S, Nagashima A, Itagaki F et al. CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. Clin. Pharmacol. Ther. 78, 647-655 (2005).
81. Hesse LM, Venkatakrishnan K, von Moltke LL, Shader RJ, Greenblatt DJ. CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. Drug Metab. Dispos. 29, 133-140 (2001).
82. Kilicarslan T, Haining RL, Rettie AE, Busto U, Tyndale RF, Sellers EM. Flunitrazepam metabolism by cytochrome P450S 2C19 and 3A4. Drug Metab. Dispos. 29, 460-465 (2001).
83. Cheng Z, Rios GR, King CD et al. Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7. Toxicol. Sci. 45, 52-57 (1998).
84. Cone EJ. Pharmacokinetics and pharmacodynamics of cocaine. J. Anal. Toxicol. 19, 459-478 (1995).
85. Warner A, Norman AB. Mechanisms of cocaine hydrolysis and metabolism in vitro and in vivo: a clarification. Ther. Drug Monit. 22, 266-270 (2000).
86. Maurer HH, Sauer C, Theobald DS. Toxicokinetics of drugs of abuse: current knowledge of the isoenzymes involved in the human metabolism of tetrahydrocannabinol, cocaine, heroin, morphine, and codeine. Ther. Drug Monit. 28, 447-453 (2006).
87. Gorelick DA, Cornish JL. The pharmacology of cocaine, amphetamines, and other stimulants. In: Principles of Addiction Medicine. Graham AW, Schultz TK, Mayo-Smith MF, Ries R, Wilford BB (Eds). American Society of Addiction Medicine, MD, USA 157-190 (2003).
88. LeDuc BW, Sinclair PR, Shuster L, Sinclair JF, Evans JE, Greenblatt DJ. Norcocaine and N-hydroxynorcocaine formation in human liver microsomes: role of cytochrome P-450 3A4. Pharmacology 46, 294-300 (1993).
89. Laizure SC, Mandrell T, Gades NM, Parker RB. Cocaethylene metabolism and interaction with cocaine and ethanol: role of carboxylesterases. Drug Metab. Dispos. 31, 16-20 (2003).
90. Figliomeni ML, Abdel-Rahman MS. Ethanol does not increase the hepatotoxicity of cocaine in primary rat hepatocyte culture. Toxicology 129, 125-135 (1998).
91. Boelsterli UA, Wolf A, Goldlin C. Oxygen free radical production mediated by cocaine and its ethanol-derived metabolite, cocaethylene, in rat hepatocytes. Hepatology 18, 1154-1161 (1993).
92. Dean RA, Harper ET, Dumaual N, Stoeckel DA, Bosron WF. Effects of ethanol on cocaine metabolism: formation of cocaethylene and norcocaethylene. Toxicol. Appl. Pharmacol. 117, 1-8 (1992).
93. Landry MJ. An overview of cocaethylene, an alcohol-derived, psychoactive, cocaine metabolite. J. Psychoactive Drugs 24, 273-276 (1992).
94. Roberts SM, Roth L, Harbison RD, James RC. Cocaethylene hepatotoxicity in mice. Biochem. Pharmacol. 43, 1989-1995 (1992).
95. Raffa JD, Grebely J, Tossonian H et al. The impact of ongoing illicit drug use on methadone adherence in illicit drug users receiving treatment for HIV in a directly observed therapy program. Drug Alcohol Depend. 89, 306-309 (2007).
96. Hinkin CH, Barclay TR, Castellon SA et al. Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav. 11, 185-194 (2007).
97. Sharpe TT, Lee LM, Nakashima AK, Elam-Evans LD, Fleming PL. Crack cocaine use and adherence to antiretroviral treatment among HIV-infected black women. J. Community Health 29, 117-127 (2004).
98. Reynolds JL, Mahajan SD, Bindukumar B, Sykes D, Schwartz SA, Nair MP. Proteomic analysis of the effects of cocaine on the enhancement of HIV-1 replication in normal human aatrocytes (NHA). Brain Res. 1123, 226-236 (2006).
99. Gekker G, Hu S, Sheng WS, Rock RB, Lokensgard JR, Peterson PK. Cocaine-induced HIV-1 expression in microglia involves σ-1 receptors and transforming growth factor-β1. Int. Immunopharmacol. 6, 1029-1033 (2006).
100. Fiala M, Eshleman AJ, Cashman J et al. Cocaine increases human immunodeficiency virus type 1 neuroinvasion through remodeling brain microvascular endothelial cells. J. Neurovirol. 11, 281-291 (2005).
101. Nair MP, Chadha KC, Hewitt RG, Mahajan S, Sweet A, Schwartz SA. Cocaine differentially modulates chemokine production by mononuclear cells from normal donors and human immunodeficiency virus type 1-infected patients. Clin. Diag. Lab. Immunol. 7, 96-100 (2000).
102. Nair MP, Mahajan S, Chadha KC et al. Effect of cocaine on chemokine and CCR-5 gene expression by mononuclear cells from normal donors and HIV-1 infected patients. Adv. Exp. Med. Biol. 493, 235-240 (2001).
103. Nair MP, Mahajan SD, Schwartz SA et al. Cocaine modulates dendritic cell-specific C type intercellular adhesion molecule-3-grabbing nonintegrin expression by dendritic cells in HIV-1 patients. J. Immunol. 174, 6617-6626 (2005).
104. Romanelli F, Smith KM, Pomeroy C. Use of club drugs by HIV-seropositive and HIV-seronegative gay and bisexual men. Top. HIV Med. 11, 25-32 (2003).
105. Lettieri JT, Fung HL. Dose-dependent pharmacokinetics and hypnotic effects of sodium γ-hydroxybutyrate in the rat. J. Pharmacol. Exp. Ther. 208, 7-11 (1979).
106. Harrington RD, Woodward JA, Hooton TM, Horn JR. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and γ-hydroxybutyrate. Arch. Intern. Med. 159, 2221-2224 (1999).
107. Reich DL, Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Can. J. Anaesth. 36, 186-197 (1989).
108. Yanagihara Y, Kariya S, Ohtani M et al. Involvement of CYP2B6 in N-demethylation of ketamine in human liver microsomes. Drug Metab. Dispos. 29, 887-890 (2001).
109. Morgan CJ, Monaghan L, Curran HV. Beyond the K-hole: a 3-year longitudinal investigation of the cognitive and subjective effects of ketamine in recreational users who have substantially reduced their use of the drug. Addiction 99, 1450-1461 (2004).
110. Hall AP, Henry JA. Acute toxic effects of 'ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management. Br. J. Anaesth. 96, 678-685 (2006).
111. Schifano F. A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities. Psychopharmacology (Berl.) 173, 242-248 (2004).
112. Roden DM, Altman RB, Benowitz NL et al. Pharmacogenomics: challenges and opportunities. Ann. Intern. Med. 145, 749-757 (2006).
113. von Moltke LL, Greenblatt DJ, Grassi JM et al. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J. Clin. Pharmacol. 38, 106-111 (1998).
114. Aarnoutse RE, Kleinnijenhuis J, Koopmans PP et al. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. Clin. Pharmacol. Ther. 78, 664-674 (2005).
115. Henry JA, Hill IR. Fatal interaction between ritonavir and MDMA. Lancet 352, 1751-1752 (1998).
116. Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ('ecstasy'). Lancet 340, 384-387 (1992).
117. Ellinwood EH, King G, Lee TH. Chronic amphetamine use and abuse. In: Psychopharmacology: the Fourth Generation of Progress CD-ROM. Watson SJ (Ed.). Lippincott, Williams & Wilkins, PA, USA (1998).
118. Lin LY, Di Stefano EW, Schmitz DA et al. Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metab. Dispos. 25, 1059-1064 (1997).
119. Hales G, Roth N, Smith D. Possible fatal interaction between protease inhibitors and methamphetamine. Antivir. Ther. (Lond.) 5, 19 (2000).
120. Theodore S, Cass WA, Nath A, Maragos WF. Progress in understanding basal ganglia dysfunction as a common target for methamphetamine abuse and HIV-1 neurodegeneration. Curr. HIV Res. 5, 301-313 (2007).
121. Theodore S, Cass WA, Maragos WF. Methamphetamine and human immunodeficiency virus protein Tat synergize to destroy dopaminergic terminals in the rat striatum. Neuroscience 137, 925-935 (2006).
122. Colfax G, Shoptaw S. The methamphetamine epidemic: implications for HIV prevention and treatment. Curr. HIV/AIDS Rep. 2, 194-199 (2005).
123. Reback CJ, Larkins S, Shoptaw S. Methamphetamine abuse as a barrier to HIV medication adherence among gay and bisexual men. AIDS Care 15, 775-785 (2003).
124. Rook EJ, van Ree JM, van den Brink W et al. Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. Basic Clin. Pharmacol. Toxicol. 98, 86-96 (2006).
125. Takeda S, Ishii Y, Iwanaga M et al. Modulation of UDP-glucuronosyltransferase function by cytochrome P450: evidence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4. Mol. Pharmacol. 67, 665-672 (2005).
126. Wang JS, DeVane CL. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab. Dispos. 31, 742-747 (2003).
127. Begre S, von Bardeleben U, Ladewig D et al. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J. Clin. Psychopharmacol. 22, 211-215 (2002).
128. Iribarne C, Berthou F, Baird S et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem. Res. Toxicol. 9, 365-373 (1996).
129. Wu D, Otton SV, Sproule BA et al. Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. Br. J. Clin. Pharmacol. 35, 30-34 (1993).
130. Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J. Acquir. Immune Defic. Syndr. 41, 563-572 (2006).
131. McCance-Katz EF, Rainey PM, Friedland G, Kosten TR, Jatlow P. Effect of opioid dependence pharmacotherapies on zidovudine disposition. Am. J. Addict. 10, 296-307 (2001).
132. McCance-Katz EF, Rainey PM, Jatlow P, Friedland G. Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262). J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 18, 435-443 (1998).
133. Rainey PM, Friedland GH, Snidow JW et al. The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. Am. J. Addict. 11, 66-74 (2002).
134. Schwartz EL, Brechbuhl AB, Kahl P, Miller MA, Selwyn PA, Friedland GH. Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection. J. Acquir. Immune Defic. Syndr. 5, 619-626 (1992).
135. Rainey PM, Friedland G, McCance-Katz EF et al. Interaction of methadone with didanosine and stavudine. J. Acquir. Immune Defic. Syndr. 24, 241-248 (2000).
136. Friedland G, Rainey P, Jatlow P, Andrews L, Damle B, McCance-Katz EF. Pharmacokinetics (PK) of didanosine (ddI) from encapsulated enteric coated bead formulation (EC) vs chewable tablet formulation in patients (pts) on chronic methadone therapy. Presented at: 14th International AIDS Conference. Barcelona, Spain, 7-12 July 2002.
137. Altice FL, Friedland GH, Cooney EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 13, 957-962 (1999).
138. Clarke SM, Mulcahy FM, Tjia J et al. Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin. Infect. Dis. 33, 1595-1597 (2001).
139. Heelon MW, Meade LB. Methadone withdrawal when starting an antiretroviral regimen including nevirapine. Pharmacotherapy 19, 471-472 (1999).
140. Stocker H, Kruse G, Kreckel P et al. Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 48, 4148-4153 (2004).
141. Marzolini C, Troillet N, Telenti A, Baumann P, Decosterd LA, Eap CB. Efavirenz decreases methadone blood concentrations. AIDS 14, 1291-1292 (2000).
142. Clarke SM, Mulcahy FM, Tjia J et al. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br. J. Clin. Pharmacol. 51, 213-217 (2001).
143. Pinzani V, Faucherre V, Peyriere H, Blayac JP. Methadone withdrawal symptoms with nevirapine and efavirenz. Ann. Pharmacother. 34, 405-407 (2000).
144. Aptivus®, tipranavir. Product information. Boehringer Ingelheim Pharmaceuticals, Inc., CT, USA (2005).
145. Cone EJ, Gorodetzky CW, Yousefnejad D, Buchwald WF, Johnson RE. The metabolism and excretion of buprenorphine in humans. Drug Metab. Dispos. 12, 577-581 (1984).
146. Picard N, Cresteil T, Djebli N, Marquet P. In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab. Dispos. 33, 689-695 (2005).
147. King CD, Green MD, Rios GR et al. The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1. Arch. Biochem. Biophys. 332, 92-100 (1996).
148. Obadia Y, Perrin V, Feroni I, Vlahov D, Moatti JP. Injecting misuse of buprenorphine among French drug users. Addiction 96, 267-272 (2001).
149. Ahmadi J, Ahmadi K, Ohaeri J. Controlled, randomized trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: a novel study. Eur. J. Clin. Invest. 33, 824-829 (2003).
150. Vidal-Trecan G, Varescon I, Nabet N, Boissonnas A. Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend. 69, 175-181 (2003).
151. Jenkinson RA, Clark NC, Fry CL, Dobbin M. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? Addiction 100, 197-205 (2005).
152. Loo HW, Yam AK, Tan TC, Peng YP, Teoh LC. Severe upper limb complications from parenteral abuse of Subutex. Ann. Acad. Med. Singap. 34, 575-578 (2005).
153. Lai SH, Yao YJ, Lo DS. A survey of buprenorphine related deaths in Singapore. Forensic Sci. Int. 162, 80-86 (2006).
154. Seet RC, Lim EC. Intravenous use of buprenorphine tablets associated with rhabdomyolysis and compressive sciatic neuropathy. Ann. Emerg. Med. 47, 396-397 (2006).
155. Bruce RD, McCance-Katz, E, Karasch ED, Moody DE, Morse GD. Pharmacokinetic interactions between buprenorphine and antiretroviral medications. Clin. Infect. Dis. 43, S216-S223 (2006).
156. McCance-Katz E, Moody DE, Morse GD et al. Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin. Infect. Dis. 43, S224-S234 (2006).
157. McCance-Katz EF, Moody DE, Smith PF et al. Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. Clin. Infect. Dis. 43(Suppl. 4), S235-S246 (2006).
158. Bruce RD, Altice FL. Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir. AIDS 20, 783-784 (2006).
159. McCance-Katz E, Pade, P, Morse GD, Moody DE, Rainey PM. Interaction between buprenorphine and atazanavir. In: College on Problems of Drug Dependence. AZ, USA (2006).
160. Laurenzana EM, Owens SM. Metabolism of phencyclidine by human liver microsomes. Drug Metab. Dispos. 25, 557-563 (1997).
161. Shebley M, Jushchyshyn MI, Hollenberg PF. Selective pathways for the metabolism of phencyclidine by cytochrome p440 2b enzymes: identification of electrophilic metabolites, glutathione, and N-acetyl cysteine adducts. Drug Metab. Dispos. 34, 375-383 (2006).
162. Bornheim LM, Lasker JM, Raucy JL. Human hepatic microsomal metabolism of δ 1-tetrahydrocannabinol. Drug Metab. Dispos. 20, 241-246 (1992).
163. Watanabe K, Matsunaga T, Yamamoto I, Funae Y, Yoshimura H. Involvement of CYP2C in the metabolism of cannabinoids by human hepatic microsomes from an old woman. Biol. Pharm. Bull. 18, 1138-1141 (1995).
164. Bland TM, Haining RL, Tracy TS, Callery PS. CYP2C-catalyzed δ9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. Biochem. Pharmacol. 70, 1096-1103 (2005).
165. Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sci. 80, 1415-1419 (2007).
166. Kosel BW, Aweeka FT, Benowitz NL et al. The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS 16, 543-550 (2002).
167. Hezode C, Roudot-Thoraval F, Nguyen S et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. [Erratum appears in Hepatology 42(2), 506]. Hepatology (2005) 42, 63-71 (2005).
168. Altice F, Safren S, Wingood G. Primary behavioral prevention of HIV transmission: tested strategies. Clin. Infect. Dis. (2007) (In Press).
169. Altice FL, Sullivan LE, Smith-Rohrberg D, Basu S, Stancliff S, Eldred L. The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention. Clin. Infect. Dis. 43(Suppl. 4), S178-S183 (2006).
170. Fisher JD, Fisher WA, Cornman DH, Amico RK, Bryan A, Friedland GH. Clinician-delivered intervention during routine clinical care reduces unprotected sexual behavior among HIV-infected patients. J. Acquir. Immune Defic. Syndr. 41, 44-52 (2006).